John R. Teerlink on Muck Rack

John R. Teerlink

As seen in: Color Research & Application, Nature, Wiley, Wiley Online Library, JAMA (The Journal of the American Medical Association), The New England Journal of Medicine, The European Heart Journal, The Lancet, Healio, Healio Cardiac/Vascular Intervention and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with John R.

Contact John R., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

New Challenges in Heart Failure: An Expert Assessment of How Real-World Observations Are Changing Our Practice

|
By Giuseppe Rosano, John R. Teerlink, Koichiro Kinugawa
| RadcliffeCardiology.com
Overview This comprehensive video series has been designed to enhance your understanding of heart failure (HF) management. Through expert discussions, we explore the real-world adoption of novel guideline-directed medical therapies (GDMTs) and their impact on patient care. We also delve into the benefits of natriuretic peptide (NP) testing, highlighting how it aids in more accurate and rapid diagnosis, which can significantly improve patient outcomes.
Open in Who Shared Issue with article?

New and future heart failure drugs - Nature Cardiovascular Research

|
By John R. Teerlink
| Nature
Abstract In the past decade, our understanding of heart failure pathophysiology has advanced significantly, resulting in the development of new medications such as angiotensin–neprilysin inhibitors, sodium–glucose cotransporter-2 inhibitors and oral soluble guanylate cyclase stimulators.
Open in Who Shared Issue with article?

Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post‐hoc analysis from EMPULSE

|
By Joao Ferreira, Jonathan Blatchford, John R. Teerlink, Mikhail Kosiborod
| Wiley Online Library
Supporting Information Filename Description ejhf369-sup-0001-FigureS1.docxWord 2007 document , 365.2 KB Appendix S1. Supporting Information. References 1, , , , , , et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial. Nat Med 2022; 28: 568–574. https://doi.org/10.1038/s41591-021-01659-1 2, , , , , , et al. Impact of empagliflozin on decongestion in acute heart failure: The EMPULSE trial. Eur Heart J 2023; 44: 41–50.
Open in Who Shared Issue with article?
See all 24 licensed articles (25 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with John R.

Contact John R., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified